David Mottola

877 total citations
14 papers, 669 citations indexed

About

David Mottola is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Organic Chemistry. According to data from OpenAlex, David Mottola has authored 14 papers receiving a total of 669 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Molecular Biology and 2 papers in Organic Chemistry. Recurrent topics in David Mottola's work include Pulmonary Hypertension Research and Treatments (8 papers), Receptor Mechanisms and Signaling (4 papers) and Heart Failure Treatment and Management (2 papers). David Mottola is often cited by papers focused on Pulmonary Hypertension Research and Treatments (8 papers), Receptor Mechanisms and Signaling (4 papers) and Heart Failure Treatment and Management (2 papers). David Mottola collaborates with scholars based in United States, United Kingdom and Germany. David Mottola's co-authors include Richard B. Mailman, David E. Nichols, William K. Brewster, Adam M. Silverstein, Brendan J.R. Whittle, Lucie H. Clapp, Robert M. Riggs, Timothy W. Lovenberg, Mark H. Lewis and David E. Nichols and has published in prestigious journals such as Journal of Applied Physiology, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

David Mottola

13 papers receiving 644 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Mottola United States	11	255	247	212	121	93	14	669
Joachim C. Burbiel Germany	14	389 1.5×	111 0.4×	42 0.2×	64 0.5×	144 1.5×	20	797
John Tam Canada	11	508 2.0×	206 0.8×	245 1.2×	17 0.1×	62 0.7×	12	1.2k
Igal Madar United States	16	253 1.0×	210 0.9×	52 0.2×	68 0.6×	24 0.3×	26	841
B. Christophe Belgium	14	348 1.4×	149 0.6×	122 0.6×	91 0.8×	101 1.1×	42	734
Yoshio Ogino Japan	16	314 1.2×	143 0.6×	59 0.3×	19 0.2×	137 1.5×	42	836
Giuseppe Alvaro Italy	21	403 1.6×	171 0.7×	99 0.5×	30 0.2×	554 6.0×	58	1.1k
Roberto Buccafusca United States	14	305 1.2×	95 0.4×	57 0.3×	56 0.5×	36 0.4×	23	710
André Uzan France	19	371 1.5×	338 1.4×	28 0.1×	63 0.5×	68 0.7×	34	815
Antonio Aliaga Canada	17	183 0.7×	172 0.7×	30 0.1×	38 0.3×	34 0.4×	32	642
Noémie Étienne France	5	127 0.5×	102 0.4×	172 0.8×	108 0.9×	16 0.2×	20	450

Countries citing papers authored by David Mottola

Since Specialization

Citations

This map shows the geographic impact of David Mottola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Mottola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Mottola more than expected).

Fields of papers citing papers by David Mottola

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Mottola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Mottola. The network helps show where David Mottola may publish in the future.

Co-authorship network of co-authors of David Mottola

This figure shows the co-authorship network connecting the top 25 collaborators of David Mottola. A scholar is included among the top collaborators of David Mottola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Mottola. David Mottola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Ghofrani, Hossein Ardeschir, Robin Osterhout, Raymond L. Benza, et al.. (2024). TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve With Treatment. A7383–A7383.

Frantz, Robert P., Raymond L. Benza, Richard N. Channick, et al.. (2021). TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. Pulmonary Circulation. 11(4). 1–7. 37 indexed citations

Kumar, Parag, et al.. (2013). Lack of a Pharmacokinetic Interaction Between Treprostinil Diolamine and Sildenafil in Healthy Adult Volunteers. Journal of Cardiovascular Pharmacology. 61(5). 444–451. 10 indexed citations

Whittle, Brendan J.R., Adam M. Silverstein, David Mottola, & Lucie H. Clapp. (2012). Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist. Biochemical Pharmacology. 84(1). 68–75. 142 indexed citations

Dingemanse, Jasper, et al.. (2010). Lack of a Pharmacokinetic Interaction Between Oral Treprostinil and Bosentan in Healthy Adult Volunteers. The Journal of Clinical Pharmacology. 50(7). 829–834. 21 indexed citations

Laliberte, Kevin, et al.. (2009). Overview of the Drug-Drug Interaction Potential with Treprostinil.. A3367–A3367. 7 indexed citations

Torres, Fernando, Anne Keogh, Robert P. Frantz, et al.. (2009). Results of the FREEDOM–C Study: A Pivotal Study of Oral Treprostinil Used Adjunctively with an ERA and/or PDE5-Inhibitor for the Treatment of PAH.. A1040–A1040. 6 indexed citations

White, R.J., Roblee P. Allen, Ferràn Torres, et al.. (2009). Sustained Plasma Concentrations of Treprostinil Following Chronic Dosing in Patients with Pulmonary Arterial Hypertension (PAH).. A3360–A3360. 10 indexed citations

Brigham, Kenneth L., et al.. (2005). Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation. Journal of Applied Physiology. 99(6). 2363–2368. 23 indexed citations

10.

Mottola, David, Jason D. Kilts, Mechelle M. Lewis, et al.. (2002). Functional Selectivity of Dopamine Receptor Agonists. I. Selective Activation of Postsynaptic Dopamine D2 Receptors Linked to Adenylate Cyclase. Journal of Pharmacology and Experimental Therapeutics. 301(3). 1166–1178. 96 indexed citations

11.

Mottola, David, Sergei Laiter, Val J. Watts, et al.. (1996). Conformational Analysis of D₁ Dopamine Receptor Agonists: Pharmacophore Assessment and Receptor Mapping. Journal of Medicinal Chemistry. 39(1). 285–296. 51 indexed citations

12.

Nichols, David E., et al.. (1994). Dopaminergic Benzo[a]phenanthridines: Resolution and Pharmacological Evaluation of the Enantiomers of Dihydrexidine, the Full Efficacy D1 Dopamine Receptor Agonist. Journal of Medicinal Chemistry. 37(15). 2453–2460. 35 indexed citations

13.

Brewster, William K., David E. Nichols, Robert M. Riggs, et al.. (1990). Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. Journal of Medicinal Chemistry. 33(6). 1756–1764. 143 indexed citations

14.

Lovenberg, Timothy W., William K. Brewster, David Mottola, et al.. (1989). Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. European Journal of Pharmacology. 166(1). 111–113. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact